196 related articles for article (PubMed ID: 30375050)
1. Echinocandin use in lung transplant recipients.
Al Jishi Y; Rotstein C; Kumar D; Humar A; Singer LG; Keshavjee S; Husain S
Clin Transplant; 2018 Dec; 32(12):e13437. PubMed ID: 30375050
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients.
Winston DJ; Limaye AP; Pelletier S; Safdar N; Morris MI; Meneses K; Busuttil RW; Singh N
Am J Transplant; 2014 Dec; 14(12):2758-64. PubMed ID: 25376267
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis.
Gatti M; Rinaldi M; Ferraro G; Toschi A; Caroccia N; Arbizzani F; Raschi E; Poluzzi E; Pea F; Viale P; Giannella M
Mycoses; 2021 Nov; 64(11):1317-1327. PubMed ID: 34387004
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.
Saliba F; Pascher A; Cointault O; Laterre PF; Cervera C; De Waele JJ; Cillo U; Langer RM; Lugano M; Göran-Ericzon B; Phillips S; Tweddle L; Karas A; Brown M; Fischer L; ;
Clin Infect Dis; 2015 Apr; 60(7):997-1006. PubMed ID: 25520332
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology of invasive fungal infections in lung transplant recipients on long-term azole antifungal prophylaxis.
Chong PP; Kennedy CC; Hathcock MA; Kremers WK; Razonable RR
Clin Transplant; 2015 Apr; 29(4):311-8. PubMed ID: 25604399
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients.
Veroux M; Macarone M; Fiamingo P; Cappello D; Gagliano M; Di Mare M; Vizcarra D; Spataro M; Giuffrida G; Sorbello M; Severino V; Veroux P
Transplant Proc; 2006 May; 38(4):1037-9. PubMed ID: 16757256
[TBL] [Abstract][Full Text] [Related]
8. Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice.
Chandwani S; Wentworth C; Burke TA; Patterson TF
Curr Med Res Opin; 2009 Feb; 25(2):385-93. PubMed ID: 19192983
[TBL] [Abstract][Full Text] [Related]
9. Safety of anidulafungin in solid organ transplant recipients.
Aguado JM; Varo E; Usetti P; Pozo JC; Moreno A; Catalán M; Len O; Blanes M; Solé A; Muñoz P; Montejo M;
Liver Transpl; 2012 Jun; 18(6):680-5. PubMed ID: 22328277
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
11. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation.
Groetzner J; Kaczmarek I; Wittwer T; Strauch J; Meiser B; Wahlers T; Daebritz S; Reichart B
J Heart Lung Transplant; 2008 Jan; 27(1):1-6. PubMed ID: 18187079
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver function tests while on caspofungin.
Doria C; Bodzin AS; Vaccino S; Daskalakis C; Krawitz S; Ramirez CB
Clin Transplant; 2011; 25(4):569-75. PubMed ID: 20662881
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
Fortún J; Muriel A; Martín-Dávila P; Montejo M; Len O; Torre-Cisneros J; Carratalá J; Muñoz P; Fariñas C; Moreno A; Fresco G; Goikoetxea J; Gavaldá J; Pozo JC; Bodro M; Vena A; Casafont F; Cervera C; Silva JT; Aguado JM;
Liver Transpl; 2016 Apr; 22(4):427-35. PubMed ID: 26709146
[TBL] [Abstract][Full Text] [Related]
14. [Role of anidulafungin in solid organ transplant recipients].
Aguado JM; Ayats J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():29-34. PubMed ID: 19572432
[TBL] [Abstract][Full Text] [Related]
15. Clinical risk factors for invasive aspergillosis in lung transplant recipients: Results of an international cohort study.
Aguilar CA; Hamandi B; Fegbeutel C; Silveira FP; Verschuuren EA; Ussetti P; Chin-Hong PV; Sole A; Holmes-Liew C; Billaud EM; Grossi PA; Manuel O; Levine DJ; Barbers RG; Hadjiliadis D; Singer LG; Husain S
J Heart Lung Transplant; 2018 Oct; 37(10):1226-1234. PubMed ID: 30139546
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
17. The use of CMVIg rescue therapy in cardiothoracic transplantation: A single-center experience over 6 years (2011-2017).
Santhanakrishnan K; Yonan N; Callan P; Karimi E; Al-Aloul M; Venkateswaran R
Clin Transplant; 2019 Aug; 33(8):e13655. PubMed ID: 31251425
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of invasive fungal infections in lung transplant recipients in Western Australia.
Chang A; Musk M; Lavender M; Wrobel J; Yaw MC; Lawrence S; Chirayath S; Boan P
Transpl Infect Dis; 2019 Jun; 21(3):e13085. PubMed ID: 30925010
[TBL] [Abstract][Full Text] [Related]
20. Echinocandin use in the neonatal intensive care unit.
Caudle KE; Inger AG; Butler DR; Rogers PD
Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
